Give me the money or the hope of having it, you will see what I can do with my Targeted Antibody Payload (TAP) technology and my proprietary antibodies. That's the message we feel ImmunoGen (IMGN) has meant to send about its upcoming clinical data presentations at the 54th annual meeting of the American Society of Hematology (ASH) to be held December 8-11, 2012 in Atlanta, GA.
The message, which has already been delivered by ImmunoGen's Daniel Junius, President and CEO, in today's a press release, is aimed at informing the oncology community about the TAP compounds they must expect to get now as well as drawing Wall Street analysts' attention to the fact that T-DM1 for HER2 breast cancer, which is expected to win approval soon, is not all the firm has in its pipeline. In his message Dr. Junius stated the following:
- ImmunoGen has ten TAP compounds now in clinical testing
- More compounds are also being developed behind these ten compounds
- Expect an increasing amount of clinical data to be reported on TAP compounds for the foreseeable future
We learned that at this year's annual ASH meeting that ImmunoGen's clinical findings will be reported for the firm's IMGN901 and Biotest's BT-062 compound. We also learned that over the course of 2013, we should expect to see data presentations with TAP compounds for the treatment of a number of types of solid tumors and hematological malignancies.
Here are some details.
IMGN901 Oral Presentation comprises:
Phase I Study of Lorvotuzumab Mertansine (LM, IMGN901) In Combination with Lenalidomide (Len) and Dexamethasone (Dex) In Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma (MM)" (Abstract #728).
BT062, An Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 weeks in each 4 week cycle: Safety and Further Evidence of Clinical Activity" (Abstract #4042).
Important
